Skip to main content
Caplight Logo









Origami Therapeutics

Origami Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://origamitherapeutics.com/

Last Round

Crowdfunding

Nov 14, 2023

Total Funding Raised

$6.62M

Company Overview

Origami Therapeutics is a biopharmaceutical company that develops disease-modifying treatments for neurodegenerative disorders using protein degraders and small molecule correctors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

protein degradationsmall-molecule drugsdrug discoveryneurodegenerative diseasetargeted protein degradationTPDbiotech R&Dundruggable targetscomputational chemistrydrug discovery platformbiotech licensingPROTACsAI-augmented drug discoverypreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Origami Therapeutics Comparables

Compare Origami Therapeutics with similar companies based on industry and business-model similarity.

Origami Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Plexium
89%
TRIMTECH Therapeutics
85%
Prazer Therapeutics
83%

Origami Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingNov 14, 2023
GrantSep 1, 2022
SeedApr 1, 2022

Origami Therapeutics Investors

Notable investors and investment history

Origami Therapeutics investors
InvestorRounds
Catalytic Impact FoundationSeed
Y CombinatorSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 30, 2026

    Partnered with Ipsen to develop a protein degrader program for a rare neurodegenerative disorder.

  • Jan 30, 2026

    Partnered with Ipsen to develop a small-molecule protein degrader program.

Origami Therapeutics Filings

Explore SEC and related filing metadata, where available.

Origami Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Origami Therapeutics's valuation, stock price, and market status.

Is Origami Therapeutics a public or private company?

Origami Therapeutics is a private company.

What is the current stock price of Origami Therapeutics?

Origami Therapeutics is a private company, so its shares have no public market price. Caplight tracks Origami Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Origami Therapeutics worth (valuation)?

Valuation information for Origami Therapeutics is not publicly available.

Can I buy Origami Therapeutics stock?

Origami Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Origami Therapeutics's last funding round?

Origami Therapeutics's most recent funding round was Crowdfunding on November 14, 2023.

Who are the main investors in Origami Therapeutics?

Key investors in Origami Therapeutics include Y Combinator.

Will Origami Therapeutics IPO soon?

No public IPO plans have been announced for Origami Therapeutics.

How can I track Origami Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in Origami Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersSan Diego, California
Employee Range6
Year Founded2015
Last FundingNov 14, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?